Marcel's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • FY 2024
Question
Marcel raised concerns about the potential for inaccuracies or 'hallucinations' in virtual cell models, particularly for rare diseases, and asked how Recursion would validate the results from such simulations.
Answer
SVP, Head of Platform, Lina Nilsson, responded that they use diverse model architectures and large benchmarking datasets to ensure accuracy. Crucially, she stressed that all model-driven insights are validated in physical labs, allowing them to focus experiments on the most promising hypotheses. For rare diseases, they leverage broad biological models to provide context and confidence where data is sparse.